Synnovation Therapeutics
Fei Zhou began their work experience as a Bachelor Student at Nanjing University from September 2006 to June 2010. They then worked as a Teaching Assistant and Research Assistant at the University of Illinois at Chicago from August 2010 to August 2016. During this time, they accomplished various projects in organic methodology development, synthesis of small molecule therapeutics, and the study of N-heteroacenes for organic field-effect transistors.
Afterwards, Fei Zhou joined Calibr at Scripps Research as a Postdoctoral Fellow from August 2016 to January 2018. Here, they delivered a preclinical candidate for malaria chemoprophylaxis, developed HPLC methods for prodrug CMC investigations, and contributed to the development of Ebola virus inhibitors.
In 2018, Fei Zhou started working at Adesis, Inc. as a Senior Chemist I until February 2022. Finally, they joined Synnovation Therapeutics in February 2022 as a Senior Research Investigator.
Fei Zhou completed a Bachelor of Science (B.S.) degree in Chemistry from Nanjing University from 2006 to 2010. Following this, Fei Zhou pursued further education and obtained a Doctor of Philosophy (Ph.D.) degree in Organic Chemistry from the University of Illinois Chicago from 2010 to 2016.
Synnovation Therapeutics
Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers.It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.